JOURNEY MEDICAL CORP
DERMNASDAQTrading Snapshot
- Day Range
- $6.24 – $6.39
- 52-Week Range
- $4.31 – $9.56
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 21.5M
- Next Earnings
- Oct 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $62M
- Last Q Revenue
- $16M
- P/E Ratio
- —
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.38
- Dividend Yield
- —
Why Investors Own DERM
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About JOURNEY MEDICAL CORP
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
